CHICAGO —
Abbott Laboratories will pay $1.6 billion to settle federal and state claims that it improperly marketed the neurologic medication Depakote for off-label uses, the company said Monday.
Abbott will pay $800 million to resolve civil allegations split among federal and state governments, $700 million in criminal penalties and $100 million to states to resolve consumer protection matters, the North Chicago-based company said.
Abbott said in previous filings with the Securities and Exchange Commission that it had earmarked $1.5 billion for a potential settlement.
Under terms of the settlement, Abbott has agreed to plead guilty to one misdemeanor violation of the Food, Drug and Cosmetic Act for misbranding. The company also will be restricted from marketing the drug for off-label uses.
Abbott, which plans to spin off its legacy drug business into a separate, publicly traded firm called AbbVie later this year, said certain compliance measures and certification requirements will transfer to the new company.
Depakote, an anti-seizure and mood-stabilizing drug, is approved by the Food and Drug Administration to treat epilepsy, bipolar disorder and migraine prevention. Lawsuits filed by four groups of whistle-blowers alleged Abbott marketed the drug for off-label uses, including for treatment of schizophrenia, agitated dementia and autism. The Department of Justice intervened in those suits to determine whether the company’s marketing of the drug violated civil and criminal laws, including fraudulently charging Medicare and Medicaid.
Those lawsuits alleged that Abbott encouraged and trained its salespeople to market Depakote off-label to nursing-home directors, geriatric doctors and other long-term care providers. The company also gave doctors illegal kickbacks to talk about off-label uses of the drug to boost sales, according to the whistle-blower suits, which were filed in federal courts in Illinois, Virginia and the District of Columbia.
Though doctors are allowed to prescribe drugs “off-label,” as the practice is known, companies are prohibited from marketing them to treat conditions not approved by the FDA.
The FDA approved Depakote in 1983 to treat certain seizures in adults and children over age 10. Since then, the drug has been approved to treatment of other types of seizures, manic episodes of bipolar disorder and the prevention of migraine headaches.
The FDA, which has ramped up its investigation of off-label drug marketing, has induced several large settlements from other drugmakers in recent years.
In November, GlaxoSmithKline PLC said it would pay the U.S. government $3 billion to settle civil and criminal charges for illegal marketing of diabetes drug Avandia and others. In 2009, Pfizer Inc. paid $2.3 billion for similar allegations about its painkiller Bextra, and Eli Lilly & Co. settled for $1.4 billion the same year for Zyprexa, used to treat schizophrenia.
Business
Abbott Laboratories to pay $1.6 billion to settle Depakote claims
- Business
-
-
Waiting for word from Bernanke, stocks move higher
It’s all about the Fed. Still.
-
Missouri moves to lift ban on foreign farm owners
Weeks before a Chinese conglomerate agreed to buy Smithfield Foods Inc. in the largest such takeover of a U.S. business, Missouri lawmakers quietly approved legislation removing a ban on foreign ownership of agricultural land.
-
NSA director says plot against Wall Street foiled
The U.S. foiled a plot to bomb the New York Stock Exchange because of the sweeping surveillance programs at the heart of a debate over national security and personal privacy, officials said Tuesday at a rare open hearing on intelligence — a set-piece for supporters of the spying.
-
Chrysler expected to formally refuse Jeep recall
In one of the biggest-ever showdowns between an automaker and the government, Chrysler on Tuesday is expected to file papers explaining its refusal to recall 2.7 million older Jeep SUVs that are at risk of catching fire in rear-end collisions.
-
Woman admits role in prearranged funeral fraud
A St. Louis County woman has admitted to a role in a pre-arranged funeral scam that allegedly bilked customers out of as much as $600 million.
-
Sprint sues to stop Dish Clearwire buyout
Sprint is suing to stop Dish Network’s buyout of wireless data network operator Clearwire. The nation’s third-largest cellphone carrier said the proposed deal violates the rights of Sprint and other Clearwire shareholders.
-
G-8 summit turns focus to clampdown on tax-dodging
World leaders at the G-8 summit declared Tuesday that governments must work together to close loopholes that allow multinational corporate giants to avoid paying taxes in their home countries.
-
Stocks edge higher on home building, low inflation
U.S. stocks were up in early trading Tuesday, boosted by government reports of gains in home construction and low inflation. Expectations that the Federal Reserve will keep in place programs meant to prop up the economy also drove the market higher.
-
With Samsung, Jay-Z’s business continues to boom
He really is more than a businessman.
-
World looks to Bernanke to clarify stimulus plans
Is the era of ultra-low interest rates nearing an end?
- More Business Headlines
-
Hoffa Mystery Still Fascinates After 4 Decades
Raw: 1 Dead in Shooting at Mo. Apartment Complex
Raw: Huge Fire Near Yosemite National Park
Raw: Obama Arrives in Berlin
3 Charged in Ohio With Enslaving Mom, Daughter
Obama Seeks G-8 Support on Syria
Raw: Volcano Erupts Near Mexico City
Kid Couture: Spending Big Bucks on Babies
Suicide Bombs Target Baghdad Mosque, Killing 29
Military Plans to Put Women in Combat Jobs
Solar Power Chargers in NYC Parks
Civil Rights Groups Sue NYPD Over Muslim Spying
Raw: First Lady, Daughters Enjoy Irish Sights
RAW: NSA Director Says 50 Plots Foiled
Boeing, Airbus Battle for Sales Supremacy
